Danielle Vaeth is Head of Growth and Strategic Development at Qbtech, a company that helps diagnose ADHD, working mostly with virtual providers. They use facial recognition and tracking to do this. Qbtech can diagnose 50% more patients than self-reporting and has approval from a big NHS study, the FDA and many peer-reviewed studies. They raised…
To address the clinical burden and enhance R&D, companies are turning to virtual solutions. This involves synthetic data, digital twin models, and AI to speed analysis. The post Why Synthetic Data is the Antidote to Clinical Trials appeared first on MedCity News.
To effectively address health disparities, organizations must implement health equity strategies that target systemic barriers and root causes. Here are strategies that can help drive comprehensive, system-wide change. The post How Health Systems Can Bridge Gaps in Health Equity appeared first on MedCity News.
Last week, the Congressional Budget Office (CBO) released a report titled “How Changes to Funding for the NIH and Changes in the FDA’s Review Times Would Affect the Development of New Drugs.” The report evaluates two scenarios: A permanent 10 percent reduction in the amount of funding that the government provides to the NIH, andA…
Thirteen House Democrats introduced eight bills to rein in Medicare Advantage and bolster traditional Medicare. The post Lawmakers Introduce Multiple Bills Aimed at Medicare Advantage Reform appeared first on MedCity News.
Ventyx Biosciences’ lead program, an oral small molecule inhibitor of NLRP3, has encouraging clinical data from separate mid-stage tests in cardiovascular disease and Parkinson’s disease. Eli Lilly said Ventyx’s pipeline has potential applications in cardiometabolic health, neurodegeneration, and autoimmunity. The post Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition appeared first…
By MATTHEW HOLT There’s been a lot of discussion lately about whether digital health is a legitimate place for venture capital. There have been lots of huge failures, very few notable successes (and certainly no “biggest companies in the world” yet, while some real giants (Walmart/Walgreens/Amazon) have come in and then got out of health…
Based on draft reconciliation language from the Energy & Commerce Committee, the Congressional Budget Office (CBO) released preliminary estimates showing proposed Medicaid changes would reduce federal Medicaid spending by $625 billion. Building on earlier KFF analysis, this analysis puts this magnitude of federal funding cuts into context by showing how the cuts relate to states’…
Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available antipsychotic drugs, which is intended to offer better efficacy and safety. The drug came from the pharma giant’s $14 billion acquisition of Karuna Therapeutics. The post FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in…
Sleep.ai’s $5.5 million in funding was led by Treasure Coast Ventures and included participation from Nurture Ventures, the Harvard Business School Alumni Angels of Greater New York and Supermoon Capital. The post Sleep.ai Secures $5.5M to Scale Sleep Intelligence Platform appeared first on MedCity News.